Michal Sarfaty Assaf Moore Elizabeth Dudnik Nir Peled
10.1097/MD.0000000000005951
Medicine (Baltimore)
2017 Jan;96(4):e5951.
CC BY-SA
https://pubmed.ncbi.nlm.nih.gov/28121940/
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Bone Neoplasms / drug therapy Carcinoma, Squamous Cell / drug therapy Lung Neoplasms / drug therapy Soft Tissue Neoplasms / drug therapy
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Bone Neoplasms / drug therapy Carcinoma, Squamous Cell / drug therapy Lung Neoplasms / drug therapy Soft Tissue Neoplasms / drug therapy Case Reports Aged Bone Neoplasms / secondary Carcinoma, Squamous Cell / secondary Fatal Outcome Female Humans Lung Neoplasms / pathology Nivolumab Soft Tissue Neoplasms / secondary Antibodies, Monoclonal Antineoplastic Agents Nivolumab
PMC5287964
28121940
Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
2017